Desacetyl cephapirin

Desacetylcephapirin (0.03-64 µg/mL; 18-20 h) inhibits clinical and subclinical Staphylococcus aureus mastitis isolates with an MIC₅₀ of 0.25 µg/mL and MIC₉₀ of 0.50 µg/mL^[1].
Desacetylcephapirin (0.03-64 µg/mL; 18-20 h) inhibits subclinical coagulase-negative staphylococci mastitis isolates with an MIC₅₀ of 0.12 µg/mL and MIC₉₀ of 0.25 µg/mL^[1].
Desacetylcephapirin (0.03-64 µg/mL; 18-20 h) shows minimal activity against clinical Escherichia coli mastitis isolates, with 89.8% not inhibited at 64 µg/mL^[1].
Desacetylcephapirin (0.008-64 µg/mL; 18-20 h) inhibits clinical Streptococcus dysgalactiae mastitis isolates with an MIC₅₀ of 0.06 µg/mL and MIC₉₀ of 0.06 µg/mL, and subclinical isolates with an MIC₅₀ of 0.12 µg/mL and MIC₉₀ of 0.12 µg/mL^[1].
Desacetylcephapirin (0.008-64 µg/mL; 18-20 h) inhibits clinical and subclinical Streptococcus uberis mastitis isolates with an MIC₅₀ of 0.50 µg/mL and MIC₉₀ of 0.50 µg/mL^[1].
Desacetyl cephapirin (0.1-1.0 ppm) formed via in vitro Cephapirin degradation demonstrates reliable recovery from beef muscle and kidney homogenates when cephapirin is spiked at concentrations of 0.1 ppm and 1.0 ppm^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.